Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00565266 · ClinicalTrials.gov registry record · Phase 3
Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)
A Phase 3 study, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 210
- Enrollment target
NCT00565266 is a Phase 3 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 210 participants.
The verdict
NCT00565266, a Phase 3 study, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 210 participants
- Enrollment target
Study Summary
Typically, people with asthma are initially prescribed a low dose of inhaled corticosteroid (ICS) medication to control asthma symptoms. If a low dose of ICS is ineffective at controlling symptoms, the addition of a second controller medication is recommended. This study will examine the effectiveness of the medication tiotropium bromide combined with a low dose of ICS at maintaining asthma control in people with moderately severe asthma.
Interventions
- DRUG beclomethasone dipropionate
- DRUG tiotropium bromide
- DRUG salmeterol xinafoate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00565266
The ClinicalTrials.gov registry entry for NCT00565266 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which beclomethasone dipropionate is the first listed.
NCT00565266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00565266 about?
NCT00565266 is a clinical study titled "Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)". Typically, people with asthma are initially prescribed a low dose of inhaled corticosteroid (ICS) medication to control asthma symptoms. If a low dose of ICS is ineffective at controlling symptoms, the addition of a second controller medication is recommended. This study will examine the effectivene...
What is the current status of trial NCT00565266?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 210 participants. The study started on 2008-05. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00565266?
The interventions under investigation include: beclomethasone dipropionate (DRUG), tiotropium bromide (DRUG), salmeterol xinafoate (DRUG).
Who is sponsoring clinical trial NCT00565266?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.